Literature DB >> 23256814

Small-molecule inhibitors of the interaction between TNF and TNFR.

Jessica M Davis1, Julie Colangelo.   

Abstract

The overexpression of TNF has been implicated in a variety of disease conditions including rheumatoid arthritis, Crohn's disease, HIV and cancer. It is presently a therapeutic target for inflammatory diseases. Many of the therapeutics currently used are biologics designed to sequester TNF, preventing it from binding with its receptors. Recent research has been focused on finding small molecules that alter the production of TNF, modulate its signal transduction pathways, or directly inhibit the binding to its receptors. Modulation of a protein-protein interaction with small molecules is an interesting and nontrivial approach. The various strategies used in obtaining small-molecule, nonpeptide, inhibitors of the TNF-TNF receptor interaction through disruption of the TNF trimer or direct inhibition of the TNF-TNF receptor interaction are presented here.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23256814     DOI: 10.4155/fmc.12.192

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  8 in total

1.  A novel small-molecule tumor necrosis factor α inhibitor attenuates inflammation in a hepatitis mouse model.

Authors:  Li Ma; Haiyan Gong; Haiyan Zhu; Qing Ji; Pei Su; Peng Liu; Shannan Cao; Jianfeng Yao; Linlin Jiang; Mingzhe Han; Xiaotong Ma; Dongsheng Xiong; Hongbo R Luo; Fei Wang; Jiaxi Zhou; Yuanfu Xu
Journal:  J Biol Chem       Date:  2014-03-14       Impact factor: 5.157

2.  Noncompetitive Allosteric Antagonism of Death Receptor 5 by a Synthetic Affibody Ligand.

Authors:  Nagamani Vunnam; Sophia Szymonski; Petra Hirsova; Gregory J Gores; Jonathan N Sachs; Benjamin J Hackel
Journal:  Biochemistry       Date:  2020-09-30       Impact factor: 3.162

Review 3.  TNF superfamily protein-protein interactions: feasibility of small- molecule modulation.

Authors:  Yun Song; Peter Buchwald
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

4.  Hydrostatin-TL1, an Anti-Inflammatory Active Peptide from the Venom Gland of Hydrophis cyanocinctus in the South China Sea.

Authors:  Ningyuan Wang; Yan Huang; An Li; Hailong Jiang; Jie Wang; Jianzhong Li; Lei Qiu; Ka Li; Yiming Lu
Journal:  Int J Mol Sci       Date:  2016-11-22       Impact factor: 5.923

5.  Cheminformatics-aided discovery of small-molecule Protein-Protein Interaction (PPI) dual inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL).

Authors:  Georgia Melagraki; Evangelos Ntougkos; Vagelis Rinotas; Christos Papaneophytou; Georgios Leonis; Thomas Mavromoustakos; George Kontopidis; Eleni Douni; Antreas Afantitis; George Kollias
Journal:  PLoS Comput Biol       Date:  2017-04-20       Impact factor: 4.475

6.  Design, Synthesis, and Evaluation of Dihydrobenzo[cd]indole-6-sulfonamide as TNF-α Inhibitors.

Authors:  Xiaobing Deng; Xiaoling Zhang; Bo Tang; Hongbo Liu; Qi Shen; Ying Liu; Luhua Lai
Journal:  Front Chem       Date:  2018-04-04       Impact factor: 5.221

7.  In Silico Discovery of Plant-Origin Natural Product Inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL).

Authors:  Georgia Melagraki; Evangelos Ntougkos; Dimitra Papadopoulou; Vagelis Rinotas; Georgios Leonis; Eleni Douni; Antreas Afantitis; George Kollias
Journal:  Front Pharmacol       Date:  2018-07-25       Impact factor: 5.810

8.  Small molecules that inhibit TNF signalling by stabilising an asymmetric form of the trimer.

Authors:  James O'Connell; John Porter; Boris Kroeplien; Tim Norman; Stephen Rapecki; Rachel Davis; David McMillan; Tracy Arakaki; Alex Burgin; David Fox Iii; Tom Ceska; Fabien Lecomte; Alison Maloney; Alex Vugler; Bruce Carrington; Benjamin P Cossins; Tim Bourne; Alastair Lawson
Journal:  Nat Commun       Date:  2019-12-19       Impact factor: 14.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.